<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931628</url>
  </required_header>
  <id_info>
    <org_study_id>2017-092</org_study_id>
    <nct_id>NCT04931628</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Salvianolic Acid on AIS</brief_title>
  <official_title>Efficacy and Safety of Salvianolic Acid on Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo No. 1 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial Tongde Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhejiang Chinese Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiaoshan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Red Cross Hospital, Hangzhou, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke has the characteristics of high morbidity, disability and fatality rate, which brings&#xD;
      heavy spiritual and economic burdens to the family, society and the country. In my country,&#xD;
      33%-50% of ischemic strokes are attributed to intracranial atherosclerosis.&#xD;
&#xD;
      Studies have shown that oxidative stress, increased blood viscosity, and damage to vascular&#xD;
      endothelial cells are important mechanisms for the development of cerebral infarction. Salvia&#xD;
      miltiorrhiza is a commonly used traditional Chinese medicine in traditional medicine in my&#xD;
      country. Salvia miltiorrhiza polyphenolic acid is the effective ingredient of salvia&#xD;
      miltiorrhiza. It is the water-soluble active part of salvia miltiorrhiza. It can resist&#xD;
      oxidation, anticoagulation, antiplatelet, cell protection, and expand blood vessels, thereby&#xD;
      achieving protection Cardiovascular system.&#xD;
&#xD;
      The purpose of this study was to evaluate the effects and adverse effects of salvianolic acid&#xD;
      on acute ischemic stroke onset within 72 hours, and to evaluate the improvement of patients'&#xD;
      ischemic area perfusion and clinical function scores.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRS score</measure>
    <time_frame>90 days</time_frame>
    <description>MRS score ≤2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebral blood flow volume (CBV)</measure>
    <time_frame>90 days</time_frame>
    <description>Cerebral blood flow volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral blood flow (CBF)</measure>
    <time_frame>90 days</time_frame>
    <description>Cerebral blood flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS score</measure>
    <time_frame>90 days</time_frame>
    <description>NIHSS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reactions (ADR)</measure>
    <time_frame>90 days</time_frame>
    <description>Adverse drug reactions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>salvianolic acid group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>salvianolic acid group 100mg+0.9%NaCl 250ml, injection, 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% NaCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9%NaCl 250ml, injection, 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salvianolic Acid</intervention_name>
    <description>salvianolic acid, injection, 100mg+0.9%NaCl 250ml, qd, 14 days</description>
    <arm_group_label>salvianolic acid group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% NaCl</intervention_name>
    <description>0.9% NaCl</description>
    <arm_group_label>0.9% NaCl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Acute ischemic stroke with the first onset, or a history of cerebral infarction but&#xD;
             with a modified Rankin Scale (mRS) score ≤1, onset within 72h;&#xD;
&#xD;
          2. CT examination to rule out cerebral hemorrhage;&#xD;
&#xD;
          3. With clear signs of nervous system positioning, the National Institutes of Health&#xD;
             Stroke Scale (NIHSS) score ≥ 4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diseases with bleeding tendency;&#xD;
&#xD;
          2. Liver and kidney dysfunction;&#xD;
&#xD;
          3. Malignant tumors or those undergoing anti-tumor treatment;&#xD;
&#xD;
          4. Allergic physique, allergic to aspirin or Salvianolic Acid;&#xD;
&#xD;
          5. Heart failure, multiple system failure;&#xD;
&#xD;
          6. Pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Haibin Dai, Professor</last_name>
    <phone>+860571-87783891</phone>
    <email>haibindai@zju.edu.cn</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke, ischemic, Acute</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

